Sanjeewani Drug And Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 10-12-2024
- Paid Up Capital ₹ 0.20 M
as on 10-12-2024
- Company Age 20 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 10.70 Cr
as on 10-12-2024
- Revenue -8.31%
(FY 2022)
- Profit 38.54%
(FY 2022)
- Ebitda 41.82%
(FY 2022)
- Net Worth 6.68%
(FY 2022)
- Total Assets 8.59%
(FY 2022)
About Sanjeewani Drug And Diagnostics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹10.70 Cr.
Kumar Singh, Urmila Thakur, and Vishal Ranjan serve as directors at the Company.
- CIN/LLPIN
U24230BR2004PTC010952
- Company No.
010952
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Sep 2004
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Siwan, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sanjeewani Drug And Diagnostics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kumar Singh  | Director | 22-Sep-2004 | Current |
| Urmila Thakur | Director | 22-Sep-2004 | Current |
| Vishal Ranjan | Director | 06-Feb-2015 | Current |
Financial Performance of Sanjeewani Drug And Diagnostics.
Sanjeewani Drug And Diagnostics Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 8.31% decrease. The company also saw a substantial improvement in profitability, with a 38.54% increase in profit. The company's net worth moved up by a moderate rise of 6.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sanjeewani Drug And Diagnostics?
In 2021, Sanjeewani Drug And Diagnostics had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Urmila Automobiles Private LimitedActive 7 years 4 monthsKumar Singh and Urmila Thakur are mutual person
- Ekawalishyam Hospitals Private LimitedActive 20 years 9 months
Kumar Singh, Urmila Thakur and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 01 Jun 2020 | ₹5.50 M | Open |
State Bank Of India Creation Date: 16 Apr 2020 | ₹2.50 M | Open |
State Bank Of India Creation Date: 01 Mar 2018 | ₹9.90 Cr | Open |
How Many Employees Work at Sanjeewani Drug And Diagnostics?
Unlock and access historical data on people associated with Sanjeewani Drug And Diagnostics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sanjeewani Drug And Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sanjeewani Drug And Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
